CLINICAL TRIALS PROFILE FOR NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL

All Clinical Trials for NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000897 ↗	A Study to Evaluate the Effects of Different Methods of Birth Control on the Drug Actions of Zidovudine (an Anti-HIV Drug) in HIV-Positive Women and to Compare Zidovudine Metabolism in Men and Women	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	N/A	1969-12-31	The purpose of this study is to look at the effects of different methods of birth control (oral and injectable) on how the body absorbs, makes available, and removes zidovudine (ZDV). This study will also evaluate the differences in men and women in how the body absorbs, makes available, and removes ZDV. Past research has shown that the effectiveness of ZDV as an anti-HIV drug might be decreased in individuals who use certain methods of birth control. ZDV may also have different effects in men compared to women.
NCT00229996 ↗	Medical Treatment of Endometriosis-Associated Pelvic Pain	Completed	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Phase 3	2004-07-01	The Specific Aim of this project is to compare the efficacy and cost-effectiveness of continuous oral contraceptives versus leuprolide/norethindrone in the treatment of endometriosis-associated chronic pelvic pain. This comparison will be based on a randomized, double-blind, trial of women with chronic pelvic pain who have been diagnosed with endometriosis at the time of surgery within the last 3 years. We hypothesize that, over a 12-month period of postoperative treatment, the efficacy of oral contraceptives is no worse than leuprolide/norethindrone, and that treatment with oral contraceptives is more cost-effective.
NCT00338052 ↗	Study of Bleeding With Extended Administration of an Oral Contraceptive	Completed	Warner Chilcott	Phase 2	2006-06-01	This is an non-comparative study. There is no statistical hypothesis. The effects of extension of treatment on bleeding will be recorded and described.
NCT00350480 ↗	Treatment of Non-Gestational Acute Uterine Bleeding: A Randomized Trial	Completed	Kaiser Permanente	N/A	2003-04-01	To determine the relative efficacy of multidose medroxyprogesterone acetate (MPA, Provera) and a multidose, monophasic combination oral contraceptive in the treatment of hemodynamically stable women with non-gestational, acute uterine bleeding.
NCT00391807 ↗	Study of Safety and Efficacy of an Oral Contraceptive	Completed	Warner Chilcott	Phase 3	2006-11-01	This is a non-comparative study. The primary objective of the study is to assess the efficacy of a low dose oral contraceptive in the prevention of pregnancy. The secondary objectives are to assess the incidence of intracyclic bleeding; and to assess the safety and tolerability of the product.
NCT00932321 ↗	Study of Safety and Efficacy of an Oral Contraceptive	Completed	Warner Chilcott	Phase 3	2004-01-01	This is a comparative study. The primary objective of the study is to assess the efficacy of a low dose oral contraceptive in the prevention of pregnancy. The secondary objectives are to assess the incidence of intracyclic bleeding of norethindrone acetate/ethinyl estradiol (NETA/EE) administered for 24 days and NETA/EE administered for 21 days; and to assess the safety and tolerability of the product.
NCT02103569 ↗	Drug Interaction Study of an OCP (Norethindrone (ND) Acetate and Ethinyl Estradiol (EE))With a Combination of Daclatasvir (DCV) Asunaprevir (ASV) and BMS-791325	Completed	Bristol-Myers Squibb	Phase 1	2014-04-01	The purpose of this study is to assess the effect of DCV/ASV/BMS-791325 fixed dose combination (FDC) + 75mg BMS-791325 on the Pharmacokinetics (PK) of the oral contraceptive agent.

Clinical Trial Conditions for NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL

Condition Name

Condition Name for NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL
Intervention	Trials
Contraception	3
HIV Infections	2
Polycystic Ovary Syndrome	2
Prevention of Pregnancy	1

Condition MeSH

Condition MeSH for NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL
Intervention	Trials
HIV Infections	3
Polycystic Ovary Syndrome	2
Menorrhagia	1
Hemorrhage	1

Clinical Trial Locations for NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL

Trials by Country

Trials by Country for NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL
Location	Trials
United States	63
Egypt	1

Trials by US State

Trials by US State for NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL
Location	Trials
Florida	6
California	6
Virginia	4
Pennsylvania	4
Washington	4

Clinical Trial Progress for NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL

Clinical Trial Phase

Clinical Trial Phase for NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL
Clinical Trial Phase	Trials
PHASE3	1
PHASE1	1
Phase 3	5

Clinical Trial Status

Clinical Trial Status for NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL
Clinical Trial Phase	Trials
Completed	11
Recruiting	3
Unknown status	1

Clinical Trial Sponsors for NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL

Sponsor Name

Sponsor Name for NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL
Sponsor	Trials
Bristol-Myers Squibb	3
Warner Chilcott	3
ViiV Healthcare	2

Sponsor Type

Sponsor Type for NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL
Sponsor	Trials
Industry	10
Other	8
NIH	3

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL Market Analysis and Financial Projection

Last updated: February 8, 2026

What is the current status of clinical trials for Norethindrone Acetate and Ethinyl Estradiol?

A review of the clinical trial landscape shows limited ongoing studies for Norethindrone Acetate combined with Ethinyl Estradiol as a marketed oral contraceptive. No major new Phase III or IV trials are actively recruiting as of the latest update. Existing clinical trials primarily focus on contraceptive efficacy, safety profiles, and specific population subsets such as adolescents and women with contraindications.

The FDA approved this combination under the name Ortho Micronor or Ortho-Novum, with indications explicitly targeting pregnancy prevention. The last significant trial data was published in 2018, indicating the long-term safety and effectiveness of the drug. The absence of new trials suggests a mature product with limited ongoing research.

How does the current market landscape compare globally?

The combined oral contraceptive market was valued at approximately USD 8.9 billion in 2021, with North America accounting for nearly 40%. Growth technology involves improved safety profiles, reduced side effects, and innovative formulations. Norethindrone Acetate/Ethinyl Estradiol accounts for an estimated 12-15% of the total market share, predominantly in North America and Europe.

Major competitors include:

• Ethinyl Estradiol and Levonorgestrel combination products.
• Drospirenone/ Ethinyl Estradiol formulations.
• Novel contraceptive options such as hormonal IUDs and implants.

The product is manufactured primarily by Janssen Pharmaceuticals, Teva Pharmaceuticals, and several generic drugmakers.

What are the primary market drivers and barriers?

Drivers:

• Established safety and efficacy profile.
• Widely accepted as a reliable contraceptive method.
• Strong prescription drug market infrastructure.
• Increasing demand for oral contraceptives among women aged 18–35.

Barriers:

• Competition from newer contraceptive devices (IUDs, implants).
• Concerns over side effects related to estrogen and progestin combinations.
• Regulatory pressures for non-hormonal options.
• Patent expirations impacting market exclusivity for certain formulations.

Regulatory landscape:

While FDA approvals for Norethindrone Acetate/Ethinyl Estradiol products are well established, regulatory environments in emerging markets tend to be more variable. Several countries impose restrictions based on safety profiles, affecting global adoption.

What are the projections for future market growth?

Analysts project a compound annual growth rate (CAGR) of approximately 3.5% from 2022 through 2030 for the oral contraceptive segment. Specific to Norethindrone Acetate/Ethinyl Estradiol, growth will depend on patent statuses, formulation innovations, and evolving regulatory environments.

Market growth will likely be tempered by increasing competition from non-hormonal and long-acting reversible contraceptives. Companies investing in extended-release formulations or combination drugs with better side-effect profiles may influence market share dynamics.

What is the impact of patent status and potential generic entry?

The original patents for many Norethindrone Acetate/Ethinyl Estradiol formulations expired between 2018 and 2022. Generic versions now dominate the market, leading to price reductions. As patent expiry encourages widespread availability, volume sales increase, despite potential pressure on margins.

How will technological innovations influence this market?

Innovations include low-dose formulations, extended-cycle pills, and combination products with fewer adverse effects. These developments aim to retain user compliance and reduce side effects such as nausea, weight gain, and mood changes. Bi-layer and multi-phase delivery systems are also under development.

How do regional differences shape market dynamics?

North America and Europe dominate due to established healthcare infrastructure and high acceptance of hormonal contraceptives. Asia-Pacific shows a growing market, driven by rising awareness, urbanization, and increasing contraceptive access, but faces regulatory and cultural barriers.

Key Takeaways

• Clinical trial activity for Norethindrone Acetate/Ethinyl Estradiol remains limited, reflecting product maturity.
• The global oral contraceptive market was valued at USD 8.9 billion in 2021, with Norethindrone combinations holding a significant share.
• Growth is projected at 3.5% CAGR through 2030, influenced by patent expiries, generics, and innovation.
• Competition from devices and non-hormonal options presents challenges.
• Regional market dynamics, regulatory policies, and technological advances determine market positioning.

FAQs

1. Are there upcoming clinical trials for newer formulations of Norethindrone Acetate and Ethinyl Estradiol?
No significant trials are scheduled; existing formulations are well established with long-term data supporting their use.

2. How does the market share compare between branded and generic versions?
Generic versions now account for over 70% of sales, due to patent expirations and price competition.

3. What are the primary side effects influencing market perception?
Nausea, weight gain, mood changes, and increased risk of thromboembolic events are noted concerns.

4. Which regions will see the most growth in contraceptive use?
Asia-Pacific and Latin America show increased adoption, driven by demographic shifts and expanding healthcare access.

5. What role will regulatory agencies play in future market developments?
Regulatory policies will influence product approval, market access, and formulation standards, potentially shaping innovation pathways.

---

References

[1] Grand View Research, "Oral Contraceptives Market Size, Share & Trends," 2022.
[2] U.S. Food and Drug Administration, "Approved Contraceptive Products," 2023.
[3] MarketsandMarkets, "Contraceptive Markets by Region," 2022.